Compare Abbott Laboratories (ABT) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs VanEck Vietnam ETF — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while VanEck Vietnam ETF trades at $18.22. The key difference: Abbott Laboratories pays a 2.63% dividend while VanEck Vietnam ETF pays none, and VanEck Vietnam ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VNM | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $19.80 |
52-Week Low | $82.57 | $14.51 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VNM trades at $18.19, down 1.62% on the day, with technical indicators signaling a bearish trend. The stock faces selling pressure from moving averages and oscillators, while support and resistance cluster around $18. Recent news highlights underperformance relative to emerging markets and global equities, compounded by Vietnam-specific risks like power grid strain from heatwaves.
The outlook remains cautious due to weak technical momentum and external headwinds. Investment opportunities hinge on Vietnam's economic resilience and potential foreign inflows from FTSE Russell's reclassification. Key risks include geopolitical tensions, climate impacts on infrastructure, and sustained underperformance versus peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
